# Hospital-based CAR-T manufacturing at cost through a public network

Source: https://onco.cc/ideas/idea-fund-public-car-t-manufacturing/  
OnCo record `idea-fund-public-car-t-manufacturing` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Academic hospitals can already make CAR-T cells for a fraction of the commercial price. A public network would scale that so more patients can be treated for less.

## Summary

Point-of-care manufacturing of CAR-T and other autologous cell therapies in a network of accredited academic hospitals, using shared vectors, harmonised processes and closed automated systems, with regulatory approval as a hospital-exemption or public product rather than a commercial licence. Spain's ARI-0001 (Hospital Clínic Barcelona) was approved by the national agency as a hospital-made CD19 CAR-T at a reported cost far below commercial products; India and Brazil have followed with domestic academic products. A network would share process, quality and pharmacovigilance and could supply public health systems at cost.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A ten-hospital public CAR-T network delivers CD19 and BCMA CAR-T with efficacy and safety non-inferior to commercial products in registry comparison, at a fully-loaded cost per treated patient under a third of commercial list prices, and doubles the number of eligible patients treated in its regions within four years.
- Rationale: ARI-0001 and academic products elsewhere demonstrate feasibility and regulatory acceptance; academic manufacturing removes the margin and much of the logistics cost. Capacity, not biology, currently rations CAR-T in most of the world.
- Proposed test: Fund a five-centre pilot with a shared vector and process, register a prospective comparative registry against commercial products, and report outcomes and cost at three years.
- Maturity: early-clinical
- Actor: clinic

## Sources

- Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022): https://doi.org/10.1038/d41573-022-00030-4

## Connected records

- ideas: [Hospital-exemption cell therapies at scale, backed by a shared registry](https://onco.cc/ideas/idea-fund-hospital-exemption-registry/), [Outcome-based annuity payments for potentially curative one-time therapies](https://onco.cc/ideas/idea-fund-pay-for-cure-annuities/), [Public-option manufacturing for essential generic cancer drugs in shortage](https://onco.cc/ideas/idea-fund-public-option-generic-oncology/), [Shared modular GMP facilities for academic personalised vaccines and cell products](https://onco.cc/ideas/idea-fund-shared-personalised-therapy-gmp/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Allogeneic (off-the-shelf) cell therapy](https://onco.cc/technologies/allogeneic-cell-therapy/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD19](https://onco.cc/targets/cd19/)
- trials: [A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)](https://onco.cc/trials/nct06464991/), [A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma](https://onco.cc/trials/nct06413498/), [CARTITUDE-4](https://onco.cc/trials/cartitude-4/), [KarMMa-3](https://onco.cc/trials/karmma-3/), [ZUMA-7](https://onco.cc/trials/zuma-7/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- key papers: [CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients](https://onco.cc/key-papers/paper-cd19-all-leukemia-j-clin-invest-2016/), [CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia](https://onco.cc/key-papers/paper-cd19-all-leukemia-blood-2015/), [Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape](https://onco.cc/key-papers/paper-upadhaya-nat-rev-drug-discov/), [Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia](https://onco.cc/key-papers/paper-cd19-all-leukemia-j-clin-oncol-2014/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-public-car-t-manufacturing.json